For those that have not read Acuity's Independent valuation of CF 33 I urge them to do so. It was submitted 5th August 2019 and this should be noted when reading the valuation.
Not pleasant reading but very useful in understanding how the Vaxinia deal was done, its terms and value to Imugene.
Especially enlightening is the methodology in arriving at a value for CF33.
After reading the report and noting the current share price, just maybe the market has got it right and Imugene is only slightly below "market value".
I hope I am wrong for all our sakes.
Not surprisingly the valuation is at the end of this announcement;
https://app.sharelinktechnologies.com/announcement/asx/6bf61fd3ec08c5611c8a2cab2bd64553
The CF33, Vaxinia and Oncarlytics Deal, page-105
-
- There are more pages in this discussion • 983 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |